Literature DB >> 23963620

Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.

Zaher Merhi1, Athena Zapantis, Dara S Berger, Sangita K Jindal.   

Abstract

PURPOSE: Serum anti-Mullerian hormone (AMH) levels estimate ovarian reserve. The purpose of this study was to identify a minimum serum AMH level that correlates with acceptable clinical pregnancy rate (CPR) in women with severe diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF). METHODS(S): A historical cohort of severe DOR participants (age ≥35) with day 3 FSH of >10 ng/mL were included (n = 120). Participants were categorized into 3 groups: AMH <0.2 (Group 1, n = 38), AMH = 0.2-0.79 (Group 2, n = 57) and AMH ≥ 0.8 (Group 3, n = 25) ng/mL. The main outcome was CPR. The number of retrieved and mature oocytes, transferred embryos, spontaneous abortion (SAB) and live birth (LB) rates were also evaluated. RESULT(S): Among the three groups, there was no difference in day 3 FSH and estradiol, total gonadotropins dose used per cycle, or LB. Participants in Group 1 were two years older than those in Group 2 and had significantly higher BMI than those in Groups 2 and 3. The three groups significantly differed in AFC (Group 1< Group 2< Group 3; p = 0.001) and cycle cancellation rate (Group 1> Group 2> Group 3; p = 0.006), and had a trend toward significance in SAB rate (Group 1> Group 2> Group 3; p = 0.06). Group 3 had significantly more retrieved and mature oocytes than Groups 1 or 2. Group 2 and 3 had significantly higher CPR per cycle start compared to Group 1. Although Group 2 had significantly fewer oocytes retrieved and mature oocytes than Group 3, CPR per cycle start for both groups was not different. ROC curve indicated that the point of maximal inflection between lower and higher CPR represents an AMH value of 0.2 ng/mL. CONCLUSION(S): AMH of 0.2 ng/mL appears to be a meaningful threshold for predicting CPR in women with severe DOR at our practice. This information can be crucial during the pre-cycle counseling of these women.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23963620      PMCID: PMC3824854          DOI: 10.1007/s10815-013-0077-z

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  22 in total

1.  Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Fertil Steril       Date:  2010-06-11       Impact factor: 7.329

2.  Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States.

Authors:  David B Seifer; Valerie L Baker; Benjamin Leader
Journal:  Fertil Steril       Date:  2010-11-13       Impact factor: 7.329

Review 3.  Weight loss by bariatric surgery and subsequent fertility.

Authors:  Zaher O Merhi
Journal:  Fertil Steril       Date:  2006-11-16       Impact factor: 7.329

4.  Relationship of bariatric surgery to Müllerian-inhibiting substance levels.

Authors:  Zaher O Merhi; Howard Minkoff; Joseph Feldman; Jerzy Macura; Carlos Rodriguez; David B Seifer
Journal:  Fertil Steril       Date:  2007-08-29       Impact factor: 7.329

Review 5.  Impact of bariatric surgery on female reproduction.

Authors:  Zaher O Merhi
Journal:  Fertil Steril       Date:  2009-08-08       Impact factor: 7.329

6.  Relevance of anti-Mullerian hormone measurement in a routine IVF program.

Authors:  C Gnoth; A N Schuring; K Friol; J Tigges; P Mallmann; E Godehardt
Journal:  Hum Reprod       Date:  2008-04-02       Impact factor: 6.918

7.  Utility of age-specific serum anti-Müllerian hormone concentrations.

Authors:  David H Barad; Andrea Weghofer; Norbert Gleicher
Journal:  Reprod Biomed Online       Date:  2010-12-13       Impact factor: 3.828

8.  A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation.

Authors:  Kannamannadiar Jayaprakasan; Bruce Campbell; James Hopkisson; Ian Johnson; Nick Raine-Fenning
Journal:  Fertil Steril       Date:  2008-11-30       Impact factor: 7.329

Review 9.  Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.

Authors:  David B Seifer; David T Maclaughlin
Journal:  Fertil Steril       Date:  2007-06-07       Impact factor: 7.329

Review 10.  The role of mullerian inhibiting substance in female reproduction.

Authors:  Gary S Nakhuda
Journal:  Curr Opin Obstet Gynecol       Date:  2008-06       Impact factor: 1.927

View more
  16 in total

1.  Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions.

Authors:  J Cohen; N Chabbert-Buffet; E Darai
Journal:  J Assist Reprod Genet       Date:  2015-10-13       Impact factor: 3.412

2.  Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?

Authors:  Nigel Pereira; Robert Setton; Allison C Petrini; Jovana P Lekovich; Rony T Elias; Steven D Spandorfer
Journal:  Womens Health (Lond)       Date:  2016-02-22

3.  Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study.

Authors:  Antonio La Marca; Valentina Grisendi; Simone Giulini; Giovanna Sighinolfi; Alessandra Tirelli; Cindy Argento; Claudia Re; Daniela Tagliasacchi; Tiziana Marsella; Sesh Kamal Sunkara
Journal:  J Assist Reprod Genet       Date:  2015-05-01       Impact factor: 3.412

Review 4.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

5.  Investigation of the Predictive Factors of Diminished Ovarian Reserve in Women Aged Less Than 40 Years and Undergoing ICSI Cycle.

Authors:  Mohammed M Laqqan; Maged M Yassin
Journal:  Reprod Sci       Date:  2022-08-24       Impact factor: 2.924

6.  Live Birth Rates in Women Under 38 Years Old with AMH Level < 1.2 ng/ml in the First In Vitro Fertilization + / - Intracytoplasmic Sperm Injection: Retrospective Study and Arguments for Care.

Authors:  Karine Morcel; Philippe Merviel; Diane Pertuisel; Pandora James; Sarah Bouée; Mathilde Le Guillou; Jean-Jacques Chabaud; Sylvie Roche; Hortense Drapier; Aurore Perrin; Damien Beauvillard
Journal:  Reprod Sci       Date:  2022-09-29       Impact factor: 2.924

7.  IVF results in patients with very low serum AMH are significantly affected by chronological age.

Authors:  Alberto Revelli; Valentina Biasoni; Gianluca Gennarelli; Stefano Canosa; Paola Dalmasso; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2016-02-18       Impact factor: 3.412

8.  The threshold effect of factors associated with spontaneous abortion in human-assisted reproductive technology.

Authors:  Fei Li; AiQin Niu; XingMei Feng; Ying Yan; Ying Chen
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

9.  What number of oocytes is appropriate for defining poor ovarian response?

Authors:  Seul Ki Kim; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

10.  Predictive value of age-specific FSH levels for IVF-ET outcome in women with normal ovarian function.

Authors:  Tingfeng Fang; Zheng Su; Liangan Wang; Ping Yuan; Ruiqi Li; Nengyong Ouyang; Lingyan Zheng; Wenjun Wang
Journal:  Reprod Biol Endocrinol       Date:  2015-06-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.